Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Bioequivalence Study to Compare Metformin / Vildagliptin (850 mg/50 mg) Versus Galvumet®

Lead Sponsor:

Reseach Laboratory of Clinical and Experimental Pharmacology

Collaborating Sponsors:

Société Arabe des Industries Pharmaceutiques SAIPH - Tunisia

Centre National Chalbi Belkahia de Pharmacovigilance CNPV - Tunisia

Conditions:

Fed Conditions

Eligibility:

All Genders

18-50 years

Phase:

PHASE1

Brief Summary

The aim of this study is to assess bioequivalence between a single oral dose from the test product Metformin / Vildagliptin tablets (850 mg as metformin hydrochloride / 50 mg as vildagliptin) manufact...

Detailed Description

The aim of this study is to assess bioequivalence between a single oral dose from the test product Metformin / Vildagliptin tablets (1000 mg as metformin hydrochloride / 50 mg as vildagliptin) manufac...

Eligibility Criteria

Inclusion

  • The subject is aged between eighteen to fifty years (18 - 50), both inclusive.
  • The subject is within the limits for his height \& weight as defined by the body mass index (BMI) range (18.5 - 30.0 Kg/m2).
  • The subject is able to understand and willing to sign the ICF.
  • The subject is willing to undergo the necessary medical examinations pre- during \& post-study.
  • There is no evidence of psychiatric disorder, antagonistic personality, and poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
  • The results of medical history, physical examination, vital signs, conducted medical laboratory tests \& ECG recording are normal as determined by the investigator.
  • The subject tested negative for Hepatitis B (HBsAg) and Hepatitis C (HCVAb).
  • For female subjects: negative pregnancy test and the woman is using two reliable contraception methods and should be non-lactating.
  • Non-
  • The subject is a heavy smoker (more than 10 cigarettes per day).
  • The subject has a history of or concurrent abuse of alcohol.
  • The subject has a history of or concurrent abuse of illicit drugs.
  • The subject has a history of hypersensitivity and/or contraindications to the study drug and any related compounds.
  • The subject is vegetarian.
  • The subject has suffered an acute illness within seven (7) days before first dosing (declared before inclusion).
  • The subject has been hospitalized within three (3) months before the study.
  • The subject has taken a prescription medication within two weeks or even an over-the-counter product (OTC) within seven (7) days before first dosing.
  • The subject has taken grapefruit containing beverages or foodstuffs within seven (7) days before first dosing (declared before inclusion).
  • The subject has a history or presence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinal, immunological, dermatological, neurological, usculoskeletal, or psychiatric diseases.
  • The subject has been participating in any clinical study (e.g. PKs, BA and BE studies) within the last 80 days prior to the present study.
  • The subject has donated blood within 80 days before first dosing.

Exclusion

  • The subject has suffered an acute illness within seven (7) days before dosing (declared after inclusion).
  • The subject has been hospitalized during the study.
  • The subject has consumed caffeine or xanthine containing beverages or foodstuffs within two (2) days before dosing and until 12 Hrs after dosing in both study periods.
  • The subject has taken a prescription medication within two (2) weeks or even an OTC within seven (7) days before first dosing and any time during the study, unless otherwise judged acceptable by the investigator.
  • The subject has taken grapefruit containing beverages or foodstuffs within seven (7) days before dosing (declared after inclusion) and any time during the study.
  • The subject underwent a radiological examination with an injection of Iodinated Contrast Media within 48 hours before first dosing.

Key Trial Info

Start Date :

February 21 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 15 2023

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT06103747

Start Date

February 21 2023

End Date

August 15 2023

Last Update

October 27 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre National Chalbi Belkahia de Pharmacovogilance

Bab Souika, Tunise, Tunisia, 1006